Circulating adipokine levels and COVID-19 severity in hospitalized patients
Authors' conclusion
Circulating adipokine levels are associated with COVID-19 hospitalization, i.e., the need for oxygen support (general ward), or the need for mechanical ventilation and other organ support in the ICU, but not mortality.
Study context
- Population
- SARS-CoV-2 infected individuals, March–December 2020; age 65 [56–74], BMI 27.0 [24.4–30.6]SARS-CoV-2 infected
- Participants
- 260 participants
- Exposure
- Plasma adipokines across COVID-19 severity (mild, severe, critical), non-COVID ICU patients and healthy matched controls
- Mildn = 30
- Severen = 159
- Criticaln = 71
- Outcome
- Plasma adipokines by COVID-19 severity
Methodological detailsmulticentre, prospective
- Multicentre
- Prospective
Main finding
As reported in the abstract
Visfatin higher in critical vs non-COVID-ICU, mild and severe (ng/mL; p < 0.05)
4.7 vs 3.4, 3.0, and 3.72
Adiponectin lower in severe and critical vs mild (µg/mL; p < 0.001)
3.65, 2.7 vs 7.9
Resistin higher in severe and critical vs mild (ng/mL; p < 0.001)
18.2, 22.0 vs 11.0
Observational data: associations, not effects.
Original publication
Circulating adipokine levels and COVID-19 severity in hospitalized patients. Int J Obes (Lond). Published 12 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →